DuoGenic StemCells (ROCO:7607) EBITDA Margin % : -582.76% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. DuoGenic StemCells's EBITDA for the six months ended in Jun. 2024 was NT$-29.67 Mil. DuoGenic StemCells's Revenue for the six months ended in Jun. 2024 was NT$5.09 Mil. Therefore, DuoGenic StemCells's EBITDA margin for the quarter that ended in Jun. 2024 was -582.76%.

DuoGenic StemCells EBITDA Margin % Historical Data

The historical data trend for DuoGenic StemCells's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells EBITDA Margin % Chart

DuoGenic StemCells Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

-876.53

-412.88

-277.28

DuoGenic StemCells Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBITDA Margin %	Get a 7-Day Free Trial			-533.10	-352.67	-255.91	-301.84	-582.76

Competitive Comparison of DuoGenic StemCells's EBITDA Margin %

For the Biotechnology subindustry, DuoGenic StemCells's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

DuoGenic StemCells EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

DuoGenic StemCells's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-37.896	/	13.667
	=	-277.28 %

DuoGenic StemCells's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-29.674	/	5.092
	=	-582.76 %

DuoGenic StemCells (ROCO:7607) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

DuoGenic StemCells EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

DuoGenic StemCells Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN

Website

https://www.dgsc.com.tw

DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines